Ahmed Abdullah Abo Elnaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Abdullah Abo Elnaga has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Dina Essam Abo-Elnour
Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 shared publications - Ibraheem M. Alkhawaldeh
Faculty of Medicine, Mutah University, Al-Karak, Jordan
2 shared publications - Ibrahim Serag
Faculty of Medicine Mansoura University, Mansoura, Egypt
2 shared publications - Mohamed Abouzid
Department of Physical Pharmacy and Pharmacokinetics Poznan University of Medical Sciences Poznan Poland
2 shared publications - Abdelaziz A. Awad
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication Abdullah Alali
Qassim University
1 shared publication
Latest Publications
- 14 September 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (22) , 2717-2731
Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
1. Sarcomas are rare and heterogeneous mesenchymal malignancies, constituting approximately 1% of adult cancers [1] and an even larger proportion of pediatric cancers [2], with a vast array of hist...
- 14 September 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (22) , 2717-2731
Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
1. Sarcomas are rare and heterogeneous mesenchymal malignancies, constituting approximately 1% of adult cancers [1] and an even larger proportion of pediatric cancers [2], with a vast array of hist...
- Open Access
- 25 June 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (8) , 108688
Safety and efficacy of tirofiban as an adjunct to endovascular thrombectomy in large vessel occlusion stroke: A systematic review and meta-analysis with GRADE assessment
- 25 June 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (8) , 108688
Open AccessSafety and efficacy of tirofiban as an adjunct to endovascular thrombectomy in large vessel occlusion stroke: A systematic review and meta-analysis with GRADE assessment
- 17 January 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (2) , 39
Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis
Background Intravenous thrombolysis remains a cornerstone in acute ischemic stroke (AIS) management, particularly in large vessel occlusion (LVO). While alteplase has long been the standard thrombolytic agent, tenecteplase has emerged as a promising alternative due to its pharmacokinetic advantages. This systematic review and meta-analysis aim to compare the efficacy and safety of tenecteplase versus alteplase in AIS patients with LVO. Methods A systematic search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, and Embase until February 2025. Studies comparing tenecteplase and alteplase in AIS patients with LVO were included. The primary outcomes were functional independence at 3 months (modified Rankin Scale [mRS] 0–1 and 0–2), mortality, and symptomatic intracranial hemorrhage (sICH). Secondary outcomes included any bleeding, adverse events, and overall complications. Pooled estimates were calculated using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). Results A total of 14 studies (N = 9641 patients) were included, comprising 5898 patients receiving alteplase and 3743 receiving tenecteplase. No significant differences were observed in 3-month functional outcomes: mRS 0–1 (RR = 0.92, 95% CI: 0.78 to 1.1, P = 0.38) and mRS 0–2 (RR = 0.95, 95% CI: 0.83 to 1.08, P = 0.44). Mortality rates were comparable between groups (OR = 1.07, 95% CI: 0.88–1.30). No significant differences were found in intracranial hemorrhage (ICH) (OR = 1.25, 95% CI: 0.96–1.62), sICH (OR = 1.1, 95% CI: 0.91–1.33), or any bleeding (OR = 1.19, 95% CI: 0.9–1.57). The pooled OR for adverse events was 0.79 (95% CI: 0.53 to 1.17), indicating a comparable safety profile. Conclusion This meta-analysis supports the non-inferiority of tenecteplase compared to alteplase in LVO-associated AIS regarding efficacy and safety. While tenecteplase offers practical advantages, including single-bolus administration and potentially lower costs, further large-scale randomized controlled trials are needed to confirm these findings and optimize thrombolytic selection in stroke care.
- 17 January 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (2) , 39
Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis
Background Intravenous thrombolysis remains a cornerstone in acute ischemic stroke (AIS) management, particularly in large vessel occlusion (LVO). While alteplase has long been the standard thrombolytic agent, tenecteplase has emerged as a promising alternative due to its pharmacokinetic advantages. This systematic review and meta-analysis aim to compare the efficacy and safety of tenecteplase versus alteplase in AIS patients with LVO. Methods A systematic search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, and Embase until February 2025. Studies comparing tenecteplase and alteplase in AIS patients with LVO were included. The primary outcomes were functional independence at 3 months (modified Rankin Scale [mRS] 0–1 and 0–2), mortality, and symptomatic intracranial hemorrhage (sICH). Secondary outcomes included any bleeding, adverse events, and overall complications. Pooled estimates were calculated using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). Results A total of 14 studies (N = 9641 patients) were included, comprising 5898 patients receiving alteplase and 3743 receiving tenecteplase. No significant differences were observed in 3-month functional outcomes: mRS 0–1 (RR = 0.92, 95% CI: 0.78 to 1.1, P = 0.38) and mRS 0–2 (RR = 0.95, 95% CI: 0.83 to 1.08, P = 0.44). Mortality rates were comparable between groups (OR = 1.07, 95% CI: 0.88–1.30). No significant differences were found in intracranial hemorrhage (ICH) (OR = 1.25, 95% CI: 0.96–1.62), sICH (OR = 1.1, 95% CI: 0.91–1.33), or any bleeding (OR = 1.19, 95% CI: 0.9–1.57). The pooled OR for adverse events was 0.79 (95% CI: 0.53 to 1.17), indicating a comparable safety profile. Conclusion This meta-analysis supports the non-inferiority of tenecteplase compared to alteplase in LVO-associated AIS regarding efficacy and safety. While tenecteplase offers practical advantages, including single-bolus administration and potentially lower costs, further large-scale randomized controlled trials are needed to confirm these findings and optimize thrombolytic selection in stroke care.